π AI is going deeper into drug discovery!
Boehringer Ingelheim is expanding its use of AI across oncology 𧬠and immunology π¬ to accelerate the discovery of new medicines. According to Reuters, the pharma company is licensing Owkin’s AI research platform and multimodal patient data to support faster and more informed drug discovery. The collaboration builds on a 2025 pilot, where AI was used with tumour samples π§« and biological datasets π to help prioritise potential drug targets. The expanded initiative will now bring in additional oncology data and generate new immunology datasets. π AI is increasingly becoming part of the drug discovery engine itself, helping pharma teams identify promising targets faster and make better R&D decisions. #AIinIndustry #GenAI #EnterpriseAI #PharmaAI #DrugDiscovery #ArtificialIntelligence #LifeSciences